Author:
Akkus Erman,Arslan Çağatay,Ürün Yüksel
Reference49 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort;Khoshkar;BJUI Compass,2022
3. Targeting treatment options for castration-resistant prostate cancer;Miller;Am J Clin Exp Urol,2021
4. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial;Corn;Lancet Oncol,2019
5. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial;Sternberg;J Clin Oncol,2009